Quick Answer
Nautilus Biotechnology, Inc. reported Net Income of -$59.00 million for fiscal year 2025.
Nautilus Biotechnology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$59.00M +16.6% |
-$70.78M -11.2% |
-$63.67M -9.9% |
-$57.92M -15.1% |
-$50.31M -222.1% |
-$15.62M |
| Diluted EPS | -$0.47 +16.1% |
-$0.56 -9.8% |
-$0.51 -10.9% |
-$0.46 +23.3% |
-$0.60 -11.1% |
-$0.54 |
| Total Assets | $191.11M -21.3% |
$242.74M -20.6% |
$305.56M -12.7% |
$350.05M -12.1% |
$398.45M +368.7% |
$85.01M |
| Cash and Equivalents | $12.39M -55.2% |
$27.65M +42.5% |
$19.40M -83.1% |
$114.52M -38.3% |
$185.62M +407.1% |
$36.61M |
| Stockholders Equity | $156.97M -24.8% |
$208.73M -21.3% |
$265.35M -15.7% |
$314.92M -13.4% |
$363.58M | $0.00 +100.0% |
| R&D Expense | $41.11M -18.6% |
$50.48M +6.8% |
$47.25M +25.4% |
$37.67M +28.3% |
$29.35M +136.1% |
$12.43M |
| Shares Outstanding | 126.47M +0.3% |
126.11M +0.8% |
125.07M +0.2% |
124.87M +0.7% |
124.05M +275.1% |
33.07M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$13.57M | +17.5% | +9.7% |
| Diluted EPS | September 30, 2025 | -$0.11 | +15.4% | +8.3% |
| Total Assets | September 30, 2025 | $200.91M | -22.6% | -5.8% |
| Cash and Equivalents | September 30, 2025 | $23.88M | +441.5% | -30.7% |
| Stockholders Equity | September 30, 2025 | $169.14M | -24.3% | -6.6% |
| R&D Expense | September 30, 2025 | $9.61M | -21.8% | -7.6% |
| Operating Income | March 31, 2021 | -$1.78M | — | -919.1% |
| Shares Outstanding | September 30, 2025 | 126.31M | +0.6% | +0.0% |
- Nautilus Biotechnology, Inc. reported Net Income of -$59.00 million for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed an increase of +16.6% in Net Income compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed an increase of +16.1% in Diluted EPS compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported Total Assets of $191.11 million for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -21.3% in Total Assets compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported Cash and Equivalents of $12.39 million for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -55.2% in Cash and Equivalents compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported Stockholders Equity of $156.97 million for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -24.8% in Stockholders Equity compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported R&D Expense of $41.11 million for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -18.6% in R&D Expense compared to the prior fiscal year.
- Nautilus Biotechnology, Inc. reported Shares Outstanding of 126.47 million shares for fiscal year 2025.
- Nautilus Biotechnology, Inc. showed an increase of +0.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: